Breo Ellipta FDA Approval History
FDA Approved: Yes (First approved May 10, 2013)
Brand name: Breo Ellipta
Generic name: fluticasone and vilanterol
Dosage form: Inhalation Powder
Company: GlaxoSmithKline plc (GSK) and Theravance, Inc.
Treatment for: COPD, Asthma
Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.
Development timeline for Breo Ellipta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.